J.ophthalmol.(Ukraine).2021;1:38-45.

http://doi.org/10.31288/oftalmolzh202113845

Received: 02 November 2020; Published on-line: 12 February 2021


Clinical experience of the use of Vasavital® in dry age-related macular degeneration and ischemic optic neuropathy

V. S. Ponomarchuk, N. I. Khramenko, N. V. Konovalova

The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine;  Odesa (Ukraine)

E-mail: kolomiets.wa@gmail.com

TO CITE THIS ARTICLE: Ponomarchuk VS, Konovalova NV,  Khramenko NI. Clinical experience of the use of Vasavital® in dry age-related macular degeneration and ischemic optic neuropathy. J.ophthalmol.(Ukraine).2020;6:38-45.   http://doi.org/10.31288/oftalmolzh202113845


Background: The chronic ischemic process caused by impaired hemodynamics in the eye and brain is a component of the pathogenesis of ischemic optic neuropathy and age-related macular degeneration, and requires prompt and adequate treatment.

Purpose: To examine the effect of a one-month course of Vasavital on the function of the visual system and regional hemodynamics in patients with dry age-related macular degeneration and those with ischemic optic neuropathy.

Material and Methods: Thirty-two patients with dry age-related macular degeneration (AMD) (mean age, 66 ± 1.5 years) and 22 patients with chronic ischemic optic neuropathy (mean age, 57.0 ± 1.4 years) underwent examination and treatment at the Department of Uveitis and Laboratory for Functional Examination of the Visual System of the Filatov institute. They received a one-month course of Vasavital-only therapy at a dose of one capsule twice a day as an outpatient treatment. Patients reported their complaints and underwent routine eye examination, studies of regional hemodynamics in the eye and brain (by ophthalmic rheography and rheoencephalography with Reocom, the computerized rheography apparatus), and electrophysiological studies of electrically evoked phosphene threshold (EEPT) and critical frequency of phosphene disappearance (CFPD) at two time points: prior to and after a one-month course of Vasavital-only therapy.

Results:  A one-month course of Vasavital-only therapy resulted in 24% and 9.6%-25% increases in ocular pulse blood filling in patients with chronic ischemic optic neuropathy and patients with age-related macular degeneration with various baseline levels of visual acuity, respectively. In addition, vascular tone in large-and small-caliber ocular vessels decreased significantly, by 12-17%, in patients with chronic ischemic optic neuropathy, and by 10-20%, in patients with age-related macular degeneration, and vascular tone in large-caliber brain vessels (in the vertebral-basilar system) decreased by 21.6% in patients with ischemic optic neuropathy. A course of Vasavital-only therapy resulted in improved optic nerve function in patients with ischemic optic neuropathy, with a 20.5% improvement in electrically evoked phosphene threshold (EEPT), and 22-63% improvement in critical frequency of phosphene disappearance (CFPD); this indicated an improved function of the peripheral as well as central retina.

Keywords: Vasavital, dry age-related macular degeneration, ischemic optic neuropathy

 

References

1.Supuran CT. Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review. Expert OpinTher Pat. 2019;24:1–7. 

Crossref   PubMed 

2.Holekamp NM. Review of neovascular age-related macular degeneration treatment options. Am J Manag Care. 2019;25(10 Suppl):S172–S181.

3.Gorusupudi A, Nelson K, Bernstein PS. The Age-Related Eye Disease 2 Study: Micronutrients in the treatment of macular degeneration. Adv Nutr. 2017;8:40–53. 

Crossref   PubMed

4.Khoo HE, Ng HS, Yap WS, et al. Nutrients for Prevention of Macular Degeneration and Eye-Related Diseases. Antioxidants (Basel). 2019;8(4).pii:E85. 

Crossref   PubMed  

5.Bourne RR, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102:575–585. 

Crossref   PubMed  

6.Pawlowska E, Szczepanska J, Koskela A, et al. Dietary Polyphenols in Age-Related Macular Degeneration: Protection against Oxidative Stress and Beyond. Oxid Med Cell Longev. 2019;2019:9682318. 

Crossref   PubMed 

7.Roberts JE, Dennison J. The Photobiology of Lutein and Zeaxanthin in the Eye. J Ophthalmol. 2015;2015:687173. 

Crossref   PubMed  

8.Martínez-Solís I, Acero N, Bosch-Morell F, et al. Neuroprotective Potential of Ginkgo biloba in Retinal Diseases. Planta Med. 2019 Jul 2. 

Crossref   PubMed

9.Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2017;7:CD000254.

Crossref  PubMed 

10.Murillo AG, Hu S, Fernandez ML. Zeaxanthin: Metabolism, Properties, and Antioxidant Protection of Eyes, Heart, Liver, and Skin. Antioxidants (Basel). 2019;8(9).pii:E390. 

Crossref   PubMed

11.Eisenhauer B, Natoli S, Liew G, Flood VM. Lutein and Zeaxanthin-Food Sources, Bioavailability and Dietary Variety in Age-Related Macular Degeneration Protection. Nutrients. 2017;9(2).pii:E120. 

Crossref   PubMed  

12.Coscas G, Cunha-vaz J, Loewenstein A, Soubrane G. Macular edema: a practical approach. Basel, Switzerland: Karger; 2010:1-9. Developments in Ophthalmology; vol 47.

Crossref   PubMed  

13.Díaz-Coránguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: Cellular basis and development. Vision Res. 2017;139:123–37. 

Crossref   PubMed  

14.Lawler T, Liu Y, Christensen K, et al. Dietary Antioxidants, Macular Pigment, and Glaucomatous Neurodegeneration: A Review of the Evidence.Nutrients. 2019;11(5).pii:E1002. 

Crossref   PubMed

15.Miller JW. Developing Therapies for Age-related Macular Degeneration: The Art and Science of Problem-solving: The 2018 Charles L. Schepens, MD, Lecture. Ophthalmol Retina. 2019;3(10):900–9. 

Crossref   PubMed  

16.Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132(2):142–9. 

Crossref   PubMed 

17.Denisova IP. [On the role of ischemic and involutionary factors in the pathogenesis of ocular degenerative disorders]. In: [Fedorov memorial lectures- 2014]. Moscow;2014. p.128-204. Russian. 

18.Frolov MA, Alkam KM. [Manifestation of ocular ischemic syndrome in patients with atherosclerotic carotid artery stenosis]. In: [Proceedings of the East-West-2013 Conference]. Ufa;2013. p.279.

19.Moisseiev E, Loewenstein A. Drug Delivery to the Posterior Segment of the Eye. Dev Ophthalmol. 2017;58:87–101. 

Crossref   PubMed 

20.Occhiutto ML, Freitas FR, Maranhao RC, Costa VP. Breakdown of the Blood-Ocular Barrier as a Strategy for the Systemic Use of Nanosystems. Pharmaceutics. 2012;4(2):252–5. 

Crossref   PubMed  

21.Ponomarchuk VS. [Diagnostics using electrical phosphenes in ophthalmology]. Odesa: Astroprint; 2018. Russian.

22.Montes P, Ruiz-Sánchez E, Rojas C, RojasP. Ginkgo biloba extract 761: a review of basic studies and potential clinical use in psychiatric disorders. CNS Neurol Disord DrugTargets. 2015;14:132-49.

Crossref   PubMed

23.Yin B, Xu Y, Wei R, LuoB. Ginkgo biloba on focal cerebral ischemia: a systematic review and meta-analysis. Am J Chin Med. 2014; 42(4):769-83.  

Crossref   PubMed  

24.Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an adjuvant therapy for progressive normal and high-tension glaucoma. Mol Vis. 2012; 18: 390-402.

25.Spadiene A, Savickiene N, Jurgeviciene N, Zalinkevicius R, Norkus A, Ostrauskas R, Skesters A, Silova A, Rodovicius H, Francaite-Daugeliene M. Effect of ginkgo extract on eye microcirculation in patients with diabetes. Cent Eur J Med. 2013; 8: 736-41. 

Crossref  

26.Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects of Ginkgo biloba extract von peripapillary retinal blood flow in normal-tension glaucoma. Korean J Ophthalmol. 2011; 25: 323-8.

Crossref   PubMed  

27.Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther. 1999 Jun;15(3):233-40. 

Crossref   PubMed 

28.Khramenko NI, Konovalova NV, Guzun OV. Regional and central hemodynamics in ischemic optic neuropathy. J Ophthalmol (Ukraine). 2018;3:3-9.

Crossref 

This papper was supported by "Ukrayinsʹka farmatsevtychna kompaniya", LLC (Ukrainian pharmaceutical company, LLC)